These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066 [TBL] [Abstract][Full Text] [Related]
26. Medical treatment of later-stage motor problems of Parkinson disease. Ahlskog JE Mayo Clin Proc; 1999 Dec; 74(12):1239-54. PubMed ID: 10593354 [TBL] [Abstract][Full Text] [Related]
27. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Widnell KL; Comella C Mov Disord; 2005; 20 Suppl 11():S30-7. PubMed ID: 15822107 [TBL] [Abstract][Full Text] [Related]
28. [Tolcapone in the management of Parkinson's disease]. Pilipovich AA; Golubev VL Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(6):71-8. PubMed ID: 18688929 [No Abstract] [Full Text] [Related]
29. First COMT inhibitor approved for Parkinson's disease. Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322 [No Abstract] [Full Text] [Related]
30. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. Pahwa R J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613 [TBL] [Abstract][Full Text] [Related]
31. Position of COMT inhibition in the treatment of Parkinson's disease. Gordin A; Kaakkola S; Teräväinen H Adv Neurol; 2003; 91():237-50. PubMed ID: 12442682 [No Abstract] [Full Text] [Related]
32. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081 [TBL] [Abstract][Full Text] [Related]
33. [Treatment of Parkinson's disease with COMT inhibitors]. Shabtai H; Korczyn A Harefuah; 2001 Oct; 140(10):935-7. PubMed ID: 11681127 [No Abstract] [Full Text] [Related]
34. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229 [TBL] [Abstract][Full Text] [Related]
35. Current pharmacotherapeutic treatment options in Parkinson's disease. Rezak M Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328 [TBL] [Abstract][Full Text] [Related]
36. The relevance of preclinical studies for the treatment of Parkinson's disease. Gerlach M; Foley P; Riederer P J Neurol; 2003 Feb; 250 Suppl 1():I31-4. PubMed ID: 12761633 [TBL] [Abstract][Full Text] [Related]
37. New Parkinson's disease drug is available. Mayo Clin Health Lett; 1998 Aug; 16(8):4. PubMed ID: 9702132 [No Abstract] [Full Text] [Related]
38. Role of tolcapone in the treatment of Parkinson's disease. Leegwater-Kim J; Waters C Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761 [TBL] [Abstract][Full Text] [Related]
39. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Müller T; Kolf K; Ander L; Woitalla D; Muhlack S Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980 [TBL] [Abstract][Full Text] [Related]
40. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. Lees AJ CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]